CTL ImmunoTherapies Company Profile

04:04 EST 22nd November 2017 | BioPortfolio

CTL ImmunoTherapies, located in Chatsworth, California, is a biotechnology company focusing on the discovery, development and manufacturing of theraputic vaccines.


9330 De Soto Ave.
United States of America


Phone: 818-678-4199
Fax: 818 678 0518

News Articles [189 Associated News Articles listed on BioPortfolio]

Top 5 Things to Know About Immunotherapies – A Review

Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss ...

eTheRNA Immunotherapies Awarded ???1 Million Grant From To Further Upgrade Its State-Of-The-Art Production Process For Trimix MRNA Immunotherapies

  Life Sciences Jobs   ...

Immunotherapies Center Stage at EADV

The designated hot topic of this year's European Academy of Dermatology and Venereology (EADV) Congress will have specialists talking about the latest developments in immunotherapies. Medscape Medic...

Combination immunotherapies and multi-modal treatment

Dr Nathan speaks with ecancer at the ACP immunotherapy workshop about combined immunotherapies and the potential pitfalls of added modalities. He outlines successes of combined ipilimumab and nivolu...

Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for...   

Takeda and Shattuck Labs partner to develop immunotherapies for cancer treatments

Takeda Pharmaceutical has entered a research collaboration with Shattuck Labs to study and develop checkpoint fusion proteins that have the potential to be used as highly differentiated, advanced immu...

Gut bacteria may be key to efficacy of immunotherapies

Why immunotherapies are successful in some individuals and not in others is a matter of huge importance to both patients and the companies that develop such treatments. The success of PD-1 and PD-L1 t...

Takeda strikes partnership to develop single-drug cancer combo immunotherapies

Japanese pharma giant Takeda has announced that it is to partner up with US-based Shattuck Labs in a collaboration to develop checkpoint fusion proteins which can be refined and utilised as highly dif...

Drugs and Medications [0 Results]


PubMed Articles [75 Associated PubMed Articles listed on BioPortfolio]

Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: a histologic and immunohistochemistry analysis.

The advent of targeted therapies using BRAF or MEK inhibitors (BRAFi or MEKi) or their combinations (BiMiC) as well as checkpoint immunotherapies based on antibodies to CTLA4 or PD1 has recently broug...

Neurological Complications of Immunotherapies-Beware of the Checkpoint Ahead.

Immunologic approaches for the treatment of multiple myeloma.

The FDA approval of two monoclonal antibodies in 2015has heralded a new era of targeted immunotherapies for multiple myeloma (MM). In this review we discuss the recent approaches using different immun...

Targeting dendritic cells through gold nanoparticles: A review on the cellular uptake and subsequent immunological properties.

Gold nanoparticles (NPs) have been proposed as a highly potential tool in immunotherapies due to its advantageous properties including customizable size and shapes, surface functionality and biocompat...

Identification of essential genes for cancer immunotherapy.

Somatic gene mutations can alter the vulnerability of cancer cells to T-cell-based immunotherapies. Here we perturbed genes in human melanoma cells to mimic loss-of-function mutations involved in resi...

Clinical Trials [22 Associated Clinical Trials listed on BioPortfolio]

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other ...

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Recent scientific advances have shown the important role of immune system against cancer. Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment and gen...

GI-4000 With Adoptive Transfer in Pancreatic Cancer

The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be complete...

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Prospective, monocentric clinical study. Patients selected for nivolumab therapy in AP-HM for melanoma and non-small cell lung cancer will be eligible. Do not include patients with conditi...

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are: - Durvalumab ...

Companies [44 Associated Companies listed on BioPortfolio]

CTL ImmunoTherapies

CTL ImmunoTherapies, located in Chatsworth, California, is a biotechnology company focusing on the discovery, development and manufacturing of theraputic vaccines.

Advaxis, Inc. and Rodman & Renshaw, LLC

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform tech...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...


OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fu...

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of s...

More Information about "CTL ImmunoTherapies" on BioPortfolio

We have published hundreds of CTL ImmunoTherapies news stories on BioPortfolio along with dozens of CTL ImmunoTherapies Clinical Trials and PubMed Articles about CTL ImmunoTherapies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CTL ImmunoTherapies Companies in our database. You can also find out about relevant CTL ImmunoTherapies Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record